Business NewsPR NewsWire • Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

OSAKA, Japan, June 11, 2021 /PRNewswire/ -- Taiko Pharmaceutical Co., Ltd. based in Osaka, Japan, hereby announced that long-lasting chlorine dioxide (ClO2) aqueous solution (*1) inactivated over 99.99% of SARS-CoV-2 (COVID-19 Virus), including its Alpha and Gamma variants (*2), in a test...

View More : https://www.prnewswire.com:443/news-releases/long-lasting-chlorine-dioxide-clo2-aqueous-solution-presented-by-taiko-phar...
Releted News by prnewswire
CGTN: Ein offenes China ist ein Segen für die Weltwirtschaft
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates USCR, ONEM, QTS, MCF; Shareholders are Encouraged to Contact the Firm
Risen Energy Unveils NewT@N at SNEC 2021, the Industry's First Mass-Produced 700W High-Efficiency Power Module
Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)
European Hematology Association: Humoral Response to the Pfizer/BioNTech BNT162b2 Vaccine Is Impaired in Patients Receiving CAR-T or High-Intensity Immunosuppressive Therapy
European Hematology Association - Pegcetacoplan Maintains a Durable Response in Patients with Paroxysmal Nocturnal Hemoglobinuria Through Week 48
European Hematology Association- First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocyte Lymphoma